US2023390348A1PendingUtilityA1

Composition for enhancing immune checkpoint blockade therapy

56
Assignee: MEIJI CO LTDPriority: Jun 14, 2018Filed: Aug 21, 2023Published: Dec 7, 2023
Est. expiryJun 14, 2038(~11.9 yrs left)· nominal 20-yr term from priority
Inventors:Hirotaka KawanabeMarie Nakamura
A23V 2200/00A23L 33/125A61P 37/06A61P 35/00A61K 31/715A61K 35/747A61P 37/04A61K 35/20C12N 1/20A23L 33/135
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The object of the invention is to provide a composition for enhancing an immune checkpoint blockade therapy. A composition forenhancing an immune checkpoint blockade therapy, which contains an exopolysaccharide of a lactic acid bacterium is provided. Preferred examples of the lactic acid bacterium include Lactobacillus bacteria (especially Lactobacillus delbrueckii subsp. bulgaricus OLL1073 R-1).

Claims

exact text as granted — not AI-modified
1 . A composition for enhancing an immune checkpoint blockade therapy, the composition comprising an exopolysaccharide of a lactic acid bacterium. 
     
     
         2 . The composition according to  claim 1 , wherein the immune checkpoint blockade therapy is a CTLA-4 (Cytotoxic T-Lymphocyte-associated Antigen 4) blockade therapy or a PD-1 (Programmed Death-1) blockade therapy. 
     
     
         3 . The composition according to  claim 1 , wherein the lactic acid bacterium is one classified into the genus  Lactobacillus.    
     
     
         4 . The composition according to  claim 1 , wherein the lactic acid bacterium is one classified into  Lactobacillus delbrueckii  subsp.  bulgaricus.    
     
     
         5 . The composition according to  claim 1 , which is fermented milk. 
     
     
         6 . A composition for increasing CCR6-positive CD8+T lymphocytes, the composition comprising an exopolysaccharide of a lactic acid bacterium. 
     
     
         7 . A non-therapeutic method for enhancing an immune checkpoint blockade therapy, the method comprising
 making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.   
     
     
         8 . A non-therapeutic method for increasing CCR6-positive CD8+T lymphocytes in a subject, the method comprising
 making a subject ingest a composition comprising an effective amount of an exopolysaccharide of a lactic acid bacterium.   
     
     
         9 . A method for increasing CCR6-positive CD8+T lymphocytes, the method comprising
 using an exopolysaccharide of a lactic acid bacterium (except for medical practices for humans).

Join the waitlist — get patent alerts

Track US2023390348A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.